# Efficacy and Safety of SCM-CGH in Patients With Steroid-Refractory or Dependent Chronic Graft-Versus-Host Disease

> **NCT04189432** · PHASE2 · UNKNOWN · sponsor: **SCM Lifescience Co., LTD.** · enrollment: 84 (estimated)

## Conditions studied

- Chronic Graft-versus-host-disease

## Interventions

- **BIOLOGICAL:** SCM-CGH
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04189432
- **Lead sponsor:** SCM Lifescience Co., LTD.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-09-28
- **Primary completion:** 2024-03-31
- **Final completion:** 2024-09-30
- **Target enrollment:** 84 (ESTIMATED)
- **Last updated:** 2023-06-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04189432

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04189432, "Efficacy and Safety of SCM-CGH in Patients With Steroid-Refractory or Dependent Chronic Graft-Versus-Host Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04189432. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*